Background. The majority of glioma-associated microglia/macrophages have been identified as M2-type macrophages with immune suppressive and tumor supportive action. Recently, the extracellular adenosine deaminase protein Cat Eye Syndrome Critical Region Protein 1 (CECR1) was shown to regulate macrophage maturation. In this study, we investigate the role of CECR1 in the regulation of the glioma-associated macrophage response. Methods. Expression of CECR1 was assessed in human glioma samples. CECR1-mediated macrophage response was studied in vitro, using donor derived CD14+ monocytes and the THP-1 monocytic cell line. The response of the human glioma cell line U87 to conditioned medium of macrophages preconditioned with recombinant human CECR1 or CECR1 silencing was also assessed. Results. CECR1 was strongly expressed in high-grade gliomas (P < .001) and correlated positively with the M2 phenotype markers in tumor-associated microglia/macrophages (TAMs) (overall, P < .05). In vitro studies confirmed the presence of a significantly higher level of CECR1 expression in M2-like macrophages exposed to U87 conditioned medium (P < .001). CECR1 knockdown or stimulation of macrophages affected differentiation toward the M2-like phenotype. Stimulation of U87 cells with conditioned medium of CECR1 knockdown or stimulated macrophages affected tumor cell proliferation and migration, coinciding with altered intracellular signaling of mitogen-activated protein kinase (MAPK). In glioma tissue samples, CECR1 expression correlated with Ki67 and MAPK signaling protein.
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The heterogeneity of glial tumor cells and the immune privileged environment of the central nervous system hamper the development of effective treatment strategies. The immune system plays a complex and largely undiscovered role in the development of gliomas. Infiltrating myeloid cells, including monocytes and macrophages, are key players in promoting tumor progression and recurrences, 1,2 as their robust presence with the accumulation of microglial cells in glioblastoma multiforme (GBM) facilitates an immune suppressive and oncogenic microenvironment. Macrophages in GBM are heterogeneous and display considerable plasticity, complicating their characterization and analysis. 2 To ease data interpretation, tumorassociated macrophages (TAMs) are divided into M1-and M2-like cells. M1-like cells express high levels of cluster of differentiation (CD)80, CD86, and major histocompatibility complex (MHC) II molecules and secrete higher levels of tumor necrosis factor α (TNF-α), interleukin (IL)-1β, and IL-12. M1-like TAMs are reportedly antitumoral and associated with better prognosis. 3, 4 However, it has been reported that (paracrine) stimulation of glial tumor cells and the hypoxic microenvironment trigger resident microglial cells and infiltrating macrophages to adopt the M2-like phenotype. 5 Indeed, M2-like TAMs outnumber their M1 counterparts in GBM. M2-like TAMs are defined by high cell surface levels of CD163, CD204, and CD14; lower levels of CD80 and MHC II; and mediation of the immunosuppressive response by secreting cytokines like IL-10, chemokine C-C ligand (CCL)20, CCL22, and prostaglandin-E 2 . 5 M2-like glioma associated microglia/macrophages are also known to mediate tumor angiogenesis by producing pro-angiogenic factors such as vascular endothelial growth factor A (VEGF-A) and urokinase-type plasminogen activator and are associated with high-grade tumors and poor clinical outcomes. 6, 7 Thus, microglia/macrophages are relevant to glial tumorigenesis and could become targets of therapeutic intervention.
In humans, the Cat Eye Syndrome Critical Region Protein 1 (CECR1) is highly expressed by macrophages. 8 Patients with genetic loss of function of CECR1 show reduced monocyte polarization into the M2 macrophage subtype, which coincides with loss of vessel integrity. 9, 10 CECR1 is a member of the adenyl-deaminase growth factor family, known for its immune modulatory function. 11 As a secreted protein, CECR1 is mainly produced by myeloid cells, with a rise in CECR1 adenosine deaminase activity reported in response to hypoxia, inflammation, and oncogenesis. 12 CECR1 has also been shown to promote macrophage proliferation, and CECR1 deficiency was previously associated with neutrophil activation, vascular damage, and inflammation. 12, 13 However, to date, the role of CECR1 in TAMs regulation in gliomas has not been explored. In this study, we investigated the role of CECR1 specifically with respect to TAMs in glial tumors.
Materials and Methods
Patient Samples
Patient samples as listed in Supplementary Tables 1 and  2 were obtained from the Biobank of the Department of Pathology, Erasmus Medical Center, Rotterdam. The use of these samples was approved by the medical ethical committee of the Erasmus MC.
Small Interfering RNA Transfection
Small interfering (si)RNA targeting CECR1 and scrambled nontargeting siRNAs were obtained from Dharmacon (GE Health Care). THP-1 derived macrophage cultures were transfected after 48 hours of para-Methoxyamphetamine (PMA) treatment, following the manufacturer's protocol (using Dharmafect transfection reagent). Efficiency of CECR1 knockdown was assessed after 24 and 48 hours at transcriptional level and protein level. For functional assays or to obtain macrophage-derived conditioned medium, siRNA transfected cells were used 24-48 hours post transfection.
Cell Cultures
CD14+ monocytes were obtained according to the manufacturer's protocols. Cells were induced with 10 ng/ mL granulocyte-macrophage colony-stimulating factor (GM-CSF) (R&D) or 10 ng/mL macrophage colony-stimulating factor (M-CSF) (Immunotools) as previously reported. 14 THP-1 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with antibiotics and 10% fetal calf serum and matured by PMA (Sigma). Interferon (IFN)-γ/lipopolysaccharide (LPS), IL-4, and IL-10 were applied to generate M1 and M2a/M2c phenotypes in vitro. Recombinant human (rh)CECR1 was used for macrophage treatment for 96 hours.
Human glioblastoma cell lines U87, U373, and U251 were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and antibiotics. U87-derived conditioned medium (U87-CM) was used to stimulate macrophages for 48 hours.
Importance of the study
• M2 TAMs are enriched in human high-grade gliomas and express high levels of CECR1.
• CECR1 mediates TAM differentiation toward M2.
• CECR1 promotes M2 TAM-mediated glial tumor cell growth and migration.
• CECR1 is a drug target with high potential for use in immune modulation therapy for treatment of patients with high-grade gliomas.
MTT Assay
U87, U373, and U251 cells were seeded in a 96-well setup followed by treatment with macrophage conditioned medium. The growth of U87 cells was monitored by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma) for 5 days. One plate without macrophage conditioned medium was measured at the same day for reference (see Supplementary material).
Migration Assay
The Oris cell migration assay kit (Platypus Technologies) was used to measure migration of PKH-67 labeled U87, U373, and U251 cells according to manufacturer's protocols in a 96-well plate setup. Macrophage conditional medium was added and after 24 hours of incubation, pictures were taken at 0 and 24 h and quantified using Image J (see Supplementary material).
RNA Isolation and Quantitative Real-Time PCR
Total RNA was isolated and reversely transcripted to cDNA from cryo-materials and macrophages. For the cryo-samples, we measured transcripts of CECR1, CD68, CD86, CD16, CD204, CD206, nitric oxide synthase (NOS)-2, IL-10, IL-12p35, and β-actin (reference gene). For in vitro experiments, transcripts of CECR1, IL-10, IL-12p35, IL-6, C-X-C motif chemokine ligand (CXCL)12, CCL18, and CCL22 were measured and normalized to β-actin level. Primers are listed in Supplementary Table 3 .
Western Blot Analysis
Total protein was loaded onto sodium dodecyl sulfatepolyacrylamide gel electrophoresis gel and blotted to nitrocellulose membranes followed by blocking and immunoblotting using specific antibodies. Incubation of secondary antibodies and detection of signals was followed using the Odyssey imaging system (Licor Bioscience) (see Supplementary material).
Flow Cytometry Analysis
Macrophages were harvested and incubated with primary antibody against CD163 (1:400; Abd Serotec) followed by Alexa Fluor-555 conjugated secondary antibody. Cells were counterstained with Hoechst 33258 and analyzed by fluorescence activated cell sorting with a Becton-Dickinson FACS Aria III (see Supplementary material).
Immunostaining Adjacent (cryo)sections were used for immunohistochemical and immunofluorescence analysis. Immunostaining and slide scanning were performed according to the protocol described previously. 15 Macrophages and U87 cells were fixed using 4% paraformaldehyde/phosphate buffered saline followed by antibody incubation. Signal areas were quantified using Image J (see Supplementary material and Table 4 ).
Statistics
Data from clinical samples were analyzed by MannWhitney U-test and Spearman correlation using SPSS 21.0. All in vitro data were tested using unpaired 2-tailed Student's t-test (significance levels P < .05). All data are presented as means ± SEM, unless otherwise stated.
Results
Expression of CECR1 Is Skewed to High-Grade Astrocytoma and Associated with the M2-like Macrophage Phenotype
Transcription of CECR1 was assessed in astrocytomas of various malignancy grades, using 2 different online Gene Expression Omnibus databases (GDS 4467, GDS1813). CECR1 was mainly expressed in GBM (Fig. 1A) . Quantitative (q)PCR analysis of astrocytoma samples from our biobank (19 astrocytomas grade II, 5 astrocytomas grade III, and 19 GBM) shows that expression of the M2-microglia/macrophage specific markers CD16, CD204, and IL-10 were significantly higher in the grade III astrocytomas and GBM than in the grade II astrocytomas (Supplementary Fig. 1B ). The microglia/macrophage markers CD68 (pan macrophage marker), CD86 (M1 marker), CD206 (M2 marker), the inducible isoform of NOS (iNOS; M1 marker), and IL-12p35 (M1 marker) were equally expressed in the lowand high-grade tumors ( Supplementary Fig. 1C, D) .
To further investigate the relation between CECR1 and microglia/macrophages in human glioma, 7 autopsy brains, 6 astrocytomas grade II, and 8 astrocytomas grade IV (GBM) were immunostained for CECR1, CD204, CD206, and CD16. CECR1 overlapped with CD204+, CD206+, and CD16+ perivascular cells in autopsy brain and lowgrade glioma (Fig. 1A, Supplementary Fig. 2A ). In GBM, the CECR1 signal mainly overlapped with CD204+ and CD16+ cells at both perivascular and tumor parenchymal locations. Areas where CECR1− cells with features of M2-like macrophages were located were also detected ( Supplementary Fig. 3A , B). Overlap between CECR1 and CD206+ cells were detected at only the peripheral perivascular locations. Quantitation of the sections revealed significant higher numbers of CECR1, CD204, CD206, and CD16+ cells in GBM versus the autopsy brains and grade II astrocytomas (Fig. 1B, Supplementary Fig. 2B ).
A qPCR dataset showed in astrocytomas grades III and IV (GBM) positive correlations of CECR1 expression with CD68, CD86, CD16, CD204, and IL-10. In astrocytomas grade III, CECR1 expression showed a negative correlation with IL-12p35. In contrast, no significant correlations between the markers iNOS, IL-12p35, CD206, and CECR1 were detected in high-grade GBM samples (Fig. 1C) .
In GBM, CECR1 colocalized with the pan macrophage markers CD68 and Iba-1 (Fig. 1D ). CECR1 colocalized with CD68 in both perivascular areas and sites remote from the vasculature in autopsy brains ( Supplementary Fig. 4A-D) , but only at In addition, CECR1 colocalized with markers of M2-like TAMs (CD204, CD163, CD16) in GBM ( Fig. 1E and F ; Supplementary Fig. 2C and D) . CECR1+/CD163+ cells were detected in only the perivascular areas in autopsy brains and in grade II astrocytomas ( Supplementary Fig. 5A-D) .
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CECR1 Is Preferentially Expressed in M2-like U87 Stimulated Macrophages In vitro
M-CSF induced (M2-like) macrophages showed a higher protein level of CECR1 than did GM-CSF induced (M1-like) macrophages ( Fig. 2A) , associated with higher protein levels of M2 phenotype markers (CD204, CD163) and higher mRNA levels of M2 cytokines (IL-10, CXCL12) ( Supplementary Fig. 6A-D ).
CECR1 protein levels in both types of macrophages were further upregulated in response to stimulation with U87 conditioned medium (U87-CM) (1.4-and 2.4-fold increase in GM-/M-CSF induced macrophage, respectively; Fig. 2A) . Similarly, expression of CECR1 was detected in THP-1 derived macrophages (Fig. 2B) . Elevated levels of CECR1 protein were detected in M2a and M2c macrophages (1.2-and 1.6-fold increase in IL-4 and IL-10 stimulated groups, respectively) and U87-CM stimulated macrophages (1.8-fold increase) compared with control group (RPMI). In contrast, in M1 macrophages (LPS+INFγ group), a lower level of CECR1 (0.8-fold change) was detected (Fig. 2B) .
CECR1 protein levels were further assessed in GM-/M-CSF induced macrophages ( Fig. 2C and D) . CECR1 protein detected by immunostaining was significantly higher in M-CSF induced (M2-like) macrophages than in GM-CSF induced (M1-like) counterparts. Furthermore, stimulation of U87-CM increased CECR1 protein levels in both M-CSF 
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and GM-CSF induced macrophages and enhanced the protein signal of the M2 marker CD163 (Fig. 2C and D) .
CECR1 Expression Induces the M2-like Macrophage Phenotype In vitro
Effective siRNA mediated silencing of CECR1 was validated by qPCR, western blotting, and immunofluorescent staining (Fig. 2E and F and Supplementary Fig. 7A and B) compared with nontargeting siRNA treated controls (siSham). Quantitative PCR, western blot analysis, and immunostaining revealed lower RNA and protein levels of the M2 marker CD163 in THP-1 macrophages silenced for CECR1 compared with the siSham controls ( Supplementary Fig. 7C and Fig. 2G, H, I ). In addition, mRNA levels of the M2 marker IL-10 decreased and those of the M1 marker CD86 increased, upon silencing for CECR1 (Fig. 2I) . Stimulation with rhCECR1 raised the levels of CD163 transcript and protein in THP-1 macrophages in a dose responsive manner (Fig. 3A and B) . Similar observations were made at the protein level using the M-CSF induced (M2-like) macrophages (Fig. 3C-E) . FACS analysis revealed increased expression of CD163 in M-CSF induced macrophages following treatment with rhCECR1 during M2 macrophage differentiation ( Supplementary  Fig. 7D ). Increased numbers of CD163+ and CD204+ cells were observed in the GBM samples with high CECR1 signals (>5% CECR1+ area per image view) compared with those Fig. 7E and F; Fig. 8A and B.
Cytokines specifically expressed by M2-like or M1-like TAMs were selected for qPCR analysis. In response to rhCECR1, THP-1 macrophages showed a dose responsive upregulation of CD163, IL-10, CXCL12, CCL18, and CCL22. Increased IL-6 was only observed in response to the highest concentration of rhCECR1 (Fig. 3F) . RhCECR1 stimulation of M-CSF induced macrophages stimulated the expression of CD163, IL-10, CXCL12, CCL18, and IL-6 (Fig. 3G) , but suppressed the expression of CCL22 (Fig. 3G) . The discrepancy with CCL22 may be the result of intrinsic differences between THP-1 derived macrophages and M-CSF induced macrophages. 16 The M1 cytokine IL-12p35 was downregulated by CECR1 in both THP-1 and peripheral M2 macrophages (Fig. 3F, G) .
CECR1 Regulates Proliferation and Migration of Glioma Cells via M2-like Macrophages
We used the GBM cell lines U87, U373, and U251 (implemented in studies with macrophages previously [17] [18] [19] ), and in order to study the effects of the macrophages on tumor progression, we first measured the effects of conditioned medium derived from THP-1 macrophages on the proliferation rates. GBM cells that received conditioned medium from rhCECR1 treated THP-1 macrophages showed higher proliferation rates (Supplementary Figs. 9A, B and 10A Fig. 10A, B) . A significant reduction in Ki67 was observed in U87 and U251 exposed to siCECR1 CM in comparison to those exposed to siSham CM ( Fig. 4D and F ; Supplementary Fig. 10C and D) . U87 and U251 cells treated with medium from THP-1 macrophages exposed to rhCECR1 resulted in rising levels of Ki67 ( Fig. 4D and  F; Supplementary Fig. 10C and F) . Direct stimulation with rhCECR1 without macrophages did not affect the proliferation rate of U87 cells (Supplementary Fig. 13A ). Next, all 3 GBM cell lines were exposed to siCECR1 CM to assess the effects on cell migration. SiCECR1 CM induced a weaker migration response than exposure to siSham CM (Fig. 4C) . Medium derived from rhCECR1 treated THP-1 macrophages enhanced the migration of GBM cells (Supplementary Fig. 9C and D; Supplementary Figs. 11  and 12 ).
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CECR1 Expression in Macrophages Mediates Paracrine Activation of the MAPK Signaling in U87 and U373 Glioma Cells
We used the mitogen activated protein kinase (MAPK) pathway consisting of extracellular signal-regulated kinase (ERK)1/2, c-Jun N-terminal kinase (JNK)/stress-activated protein kinase (SAPK), and P38 signaling because it plays crucial roles in tumor cell survival and motility. 20, 21 Serum-free medium starved glioma cells (U87 and U373) were stimulated for 10 and 20 minutes by siCECR1 CM or siSham CM. Phospho-ERK1/2, total ERK1/2, and phospho-JNK/SAPK/total JNK/SAPK ratios decreased in U87 and U373 cells exposed to THP-1 siCECR1 CM at both time points (Fig. 5A-D and Supplementary Fig. 14A-D) . The transcription factor c-Jun is a potential downstream target of JNK/SAPK. The phospho-c-Jun (ser73)/total c-Jun ratio was significantly reduced in the U87 and U373 cells exposed to THP-1 siCECR1 CM at 20 minutes post stimulation only (Fig. 5E-F and Supplementary Fig. 14E, F) . Immunostaining for phospho-c-Jun showed a reduced signal in U87 with THP-1 siCECR1 CM treatment ( Fig. 5G  and H) . In contrast, medium derived from THP-1 macrophages treated with rhCECR1 increased phospho-protein/total protein ratios of both ERK1/2 and JNK/SAPK in U87 cells ( Supplementary Fig. 15A and D) . Direct rhCECR1 treatment of U87 cells without macrophage mediation did not increase phospho-ERK1/2 and phospho-JNK/SAPK ratios ( Supplementary Fig. 13B ). These data indicate that the MAPK signaling pathways in U87 and U373 cells are activated by a CECR1-mediated paracrine effect from macrophages.
Expression of CECR1 Correlates with Increased Levels of Ki67 Positive Cells and Phosphorylation of ERK1/2 and JNK/SAPK in Patient GBM Samples
Thirty-three GBM surgical samples were selected for immunohistochemical evaluation and divided into 2 groups based on the median of the percentage of CECR1+ areas per image view (Fig. 6A-C) . The number of Ki67+ cells and the percentage of positive areas for phospho-ERK1/2, phospho-JNK/SAPK, and phospho-c-Jun (ser73) proteins were analyzed and compared between the 2 groups ( Fig. 6A-C) . A significantly higher number of Ki67+ cells were counted in the samples with high CECR1 signal (Fig. 6C) . The number of Ki67+ cells is positively correlated with the percentage of CECR1+ area (Fig. 6D) . In addition, phospho-ERK1/2, phospho-JNK/SAPK, and phospho-c-Jun signals were significantly higher in the CECR1 high group. The ratios of the phospho-ERK1/2-total ERK1/2, phospho-JNK/SAPK-total JNK/SAPK, and phospho-c-Jun/total c-Jun signals correlated positively with the percentage of CECR1+ areas in GBM samples (Fig. 6D) . In addition, phospho-ERK1/2-total ERK1/2, phospho-JNK/SAPK-total JNK/SAPK, and phospho-cJun/total c-Jun signals were positively correlated with the number of Ki67+ cells in GBM specimens ( Supplementary  Fig. 16 ).
Discussion
The main function of CECR1 is conversion of extracellular adenosine to inosine by replacing an amino with a hydroxyl group. 22 CECR1 itself can also directly bind to, and possibly activate, the adenosine receptors A 2A R and A 2B R. 23 In general, adenosine limits the production of proinflammatory factors such as tumor necrosis factor α and IL-12, and increases the production of anti-inflammatory cytokines, including IL-10. 24, 25 During M1-type inflammations, LPS stimulation of macrophages upregulates the adenosine receptor A 2A R, which increases in turn the sensitivity of M1 macrophages to adenosine. This provides a feedback inhibitory mechanism to the M1 response by mediating a switch toward a milder M2 response. 26 In GBM, mainly M2 polarized cells are found with high levels of CECR1 production. This should reduce local adenosine levels and promote a more pro-inflammatory M1-based feedback response. However, M1 TAMs are in the minority compared with M2 TAMs in GBM. As indicated by previous studies, CECR1 itself can also directly activate adenosine receptor associated pathways independently of CECR1 catalytic activity and thus is capable of promoting the same anti-inflammatory reaction as observed with adenosine stimulation. 23 Previous studies, in addition to our own findings, have highlighted the crucial role of CECR1 in promoting M2 macrophage polarization. 9 , 10 More research on the exact (possibly independent of catalytic activity) working mechanism is required to fully elucidate this process. CECR1 also appears to be critical in the modulation of the immune system in general, as heterozygous CECR1 mutation is associated with increased antibody deficiency and overall immune dysregulation in the affected patients. 27 A significant rise in activated CECR1 levels in the circulation of systemic lupus erythematosus relapse patients also highlights an important role for CECR1 in the modulation of the (auto)immune response. 28 Other reports have implicated CECR1 as possibly a crucial regulator of neutrophils, as reduced adenosine deaminase activity in biallelic CECR1 mutation patients is an important causative factor for increased neutrophil activity that coincided with systemic vasculitis. 13 Others have confirmed that CECR1 mutations with deleterious protein function are indeed strongly 
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associated with systemic vasculopathy in addition to lacunar strokes. 9, 10 This phenotype was mimicked in zebrafish models in which knockdown of the zebrafish homologue of CECR1 caused intracranial hemorrhages and neutropenia. The clinical pathologies observed in patients with CECR1 deficiency could be partially reduced by anti-tumor necrosis factor therapy, 29 further strengthening the association between CECR1 deficiency with a systemic hyperactivated inflammation response.
The link between CECR1 deficiencies and vasculopathy is further strengthened by a report on 2 patients with biallelic CECR1 mutations and histories of vasculitis and intracranial hemorrhages. 13 In our current study, CECR1-expressing immune cells were observed at the perivascular areas of the gliomas in particular-possibly reflecting the modulation of immune cells by CECR1 leading to progressive malfunction of the endothelial barrier function of glioma vasculature. Based on these reports and our own observations, we hypothesize that the influence of CECR1 on immune cells, and on macrophage polarization especially, seems to predominantly impact the systemic and cerebral vasculature, and could affect the tumor vasculature in GBM. 12 The fraction of resident microglia and TAMs reportedly constitute up to 30% of the total cell population of GBM. 30 Glioma cells are capable of actively reprogramming the TAMs in order to support tumor progression. 5 Based on expression profiling of mouse gliomas, subtyping beyond the classic M1 and M2 poles has been introduced and M2a (Th2, anti-pathogens response), M2b (Th2, immune regulatory), and M2c (immune modulatory and tissue remodeling) 31 TAMs are now being recognized. 32 These 3 subtypes can be differentially activated in malignant tumors via IL-4/IL-13 (for M2a), 31 CXC receptor 3(+) B cells, 33 IL-21/ IFN-γ pathways (for M2b), 34 and IL-10 or M-CSF stimulation (for M2c). 31, 35 The M2 subtypes have been shown to contribute to carcinogenesis in various ways, including contact-dependent dispersion of carcinoma cell aggregates (M2a), 36 supporting tumor progression (M2b), 34 and active suppression of immune surveillance (M2c). Expression analysis of typical M1 and M2a, b, and c subtype markers validated the presence of these TAM subtypes in human gliomas. Of note, over 50% of genes in TAMs in murine glioma do not match with any genes that typically characterize these 4 macrophage subtypes. In addition, a recent study has presented evidence that the TAM phenotype in GBM could also resemble the unpolarized Ω macrophage phenotype. 37 It remains unclear whether the glioma TAMs constitute a unique phenotype that is not found in macrophage populations in nonneoplastic tissues. Further investigations of the influence of CECR1 on the expression of the M1 and M2a, b, and c markers may reveal specific CECR1-mediated effects on TAM polarization.
The modest effects of CECR1 knockdown in vitro contrasted with the strong correlation between CECR1 protein expression levels and phospho-JNK, phospho-ERK1/2, and phospho-c-Jun levels that were found in the tumor samples (which were more significant). This discrepancy could be explained by the isolated conditions in our experimental setup in vitro. We designed the study to investigate the direct paracrine effects of CECR1 modulation in macrophages on GBM cell response and chose to use conditioned medium derived from the siCECR1 treated macrophages to stimulate GBM cells. In vivo, direct interaction with CECR1 highexpressing macrophages with the surrounding tumor environment-including tumor cells and other (inflammatory) cells such as subsets of CD3+ T cells, 38 microglia, 2 and neutrophils 39 -could further enhance JNK and ERK signaling.
In conclusion, the current study has demonstrated a CECR1-mediated cross-talk mechanism between macrophages and glioma cells. Continuous CECR1 autocrine stimulation of macrophages enables M2-like TAMs to stimulate MAPK and c-Jun signaling in glioma cells via paracrine activation, leading to higher proliferation and motility rates in tumor glioma cells. Based on our findings, CECR1 could become a suitable drug target for selective modulation of the M2-like TAMs in glioma.
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